Cargando…

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay

BACKGROUND: We have developed and analytically validated a next-generation sequencing (NGS) assay to classify microsatellite instability (MSI) in formalin-fixed paraffin-embedded (FFPE) tumor specimens. METHODOLOGY: The assay relies on DNA-seq evaluation of insertion/deletion (indel) variability at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pabla, Sarabjot, Andreas, Jonathan, Lenzo, Felicia L., Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Nesline, Mary K., Wang, Yirong, Gardner, Mark, Conroy, Jeffrey M., Papanicolau-Sengos, Antonios, Morrison, Carl, Glenn, Sean T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718258/ https://www.ncbi.nlm.nih.gov/pubmed/31497248 http://dx.doi.org/10.18632/oncotarget.27142

Ejemplares similares

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021)

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
por: Pabla, Sarabjot, et al.
Publicado: (2021)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019)

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
por: Zhang, Tian, et al.
Publicado: (2020)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
por: Paluch, Benjamin E, et al.
Publicado: (2016)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
por: Pabla, Sarabjot, et al.
Publicado: (2019)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
por: Conroy, Jeffrey M., et al.
Publicado: (2019)

Oncologist uptake of comprehensive genomic profile guided targeted therapy
por: Nesline, Mary K., et al.
Publicado: (2019)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Interaction between Microsatellite Instability (MSI) and Tumor DNA Methylation in the Pathogenesis of Colorectal Carcinoma
por: Jasmine, Farzana, et al.
Publicado: (2021)

Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing
por: Wei, Lei, et al.
Publicado: (2016)

Mutations in the WTX - gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
por: Scheel, Silvio K, et al.
Publicado: (2010)

Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients
por: Berardinelli, Gustavo Noriz, et al.
Publicado: (2018)

MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer
por: Herbreteau, Guillaume, et al.
Publicado: (2021)

xDEEP-MSI: Explainable Bias-Rejecting Microsatellite Instability Deep Learning System in Colorectal Cancer
por: Bustos, Aurelia, et al.
Publicado: (2021)

DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data
por: Swaerts, Koen, et al.
Publicado: (2023)

EMAST Type of Microsatellite Instability—A Distinct Entity or Blurred Overlap between Stable and MSI Tumors
por: Vuković Đerfi, Kristina, et al.
Publicado: (2023)

Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort
por: Kullmann, Friederike, et al.
Publicado: (2023)

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H)
por: Kanbour, Aladdin, et al.
Publicado: (2019)

A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients
por: Zheng, Kai, et al.
Publicado: (2020)

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2022)

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
por: Gatalica, Zoran, et al.
Publicado: (2016)

Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation
por: McCarthy, Aoife J, et al.
Publicado: (2018)

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
por: Barata, Pedro, et al.
Publicado: (2020)

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
por: Palmeri, M., et al.
Publicado: (2021)

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Microsatellite Instability-Related ACVR2A Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers
por: Zhao, Liqin, et al.
Publicado: (2020)

Editorial: Microsatellite and microsatellite instability
por: How-Kit, Alexandre, et al.
Publicado: (2023)

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
por: Moschetta, Michele, et al.
Publicado: (2017)

Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas?
por: Luong, Tu Vinh, et al.
Publicado: (2020)

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
por: Gim, Gahyun, et al.
Publicado: (2022)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Microsatellite instability-related prognostic risk score (MSI-pRS) defines a subset of lung squamous cell carcinoma (LUSC) patients with genomic instability and poor clinical outcome
por: Hu, Zixin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qham6vu07sd8gk5hba989q8smm